Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis

Advanced Drug Delivery Reviews

Volumn 61, Issue 4, 2009, Pages 319-326

  Nishikawa, Makiya ^a   Hashida, Mitsuru ^a,b   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Catalase, Targeted delivery; Liver; PEGylation; Reactive oxygen species; Receptor mediated endocytosis; Tumor metastasis

Indexed keywords

CATALASE, TARGETED DELIVERY; PEGYLATION; REACTIVE OXYGEN SPECIES; RECEPTOR-MEDIATED ENDOCYTOSIS; TUMOR METASTASIS;

CHEMICAL MODIFICATION; ENZYMES; HYDROGEN; HYDROGEN PEROXIDE; LIVER; OXYGEN; PATHOLOGY;

TUMORS;

1,6 HEXANEDIAMINE; ASIALOGLYCOPROTEIN RECEPTOR; BOVINE SERUM ALBUMIN; CATALASE; ETHYLENEDIAMINE; FERRITIN; GALACTOSE; GALACTOSE CATALASE IN 111; GELATIN; HEMOGLOBIN; HYDROGEN PEROXIDE; INDIUM 111; LACTOFERRIN; MACROGOL; MANNOSE; MANNOSE BINDING PROTEIN; MANNOSE CATALASE IN 111; MANNOSE RECEPTOR; MYOGLOBIN; N,N' DIMETHYL 1,3 PROPANEDIAMINE; POLYMER; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; SUCCINYL CATALASE IN 111; TRANSFERRIN; UNCLASSIFIED DRUG; URATE OXIDASE;

CATALASE DEFICIENCY; CATIONIZATION; CELL PROTECTION; CELL STRAIN HEPG2; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG UPTAKE; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME GLYCOSYLATION; HUMAN; HYDROGEL; ISOTOPE LABELING; KUPFFER CELL; LIPID PEROXIDATION; LIVER ISCHEMIA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PEGYLATION; PERITONEUM MACROPHAGE; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SUCCINYLATION; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALASE; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 64149085276     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.01.001     Document Type: Review

References (145)

1. Storz P. Mitochondrial ROS-radical detoxification, mediated by protein kinase D. Trends Cell Biol. 17 (2007) 13-18
2. Ouzounis C.A., Kunin V., Darzentas N., and Goldovsky L. A minimal estimate for the gene content of the last universal common ancestor-exobiology from a terrestrial perspective. Res. Microbiol. 157 (2006) 57-68
3. Cockell C.S. Biological effects of high ultraviolet radiation on early earth-a theoretical evaluation. J. Theor. Biol. 193 (1998) 717-729
4. Sen C.K., and Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 10 (1996) 709-720
5. Suzuki Y.J., Forman H.J., and Sevanian A. Oxidants as stimulators of signal transduction. Free Radic. Biol. Med. 22 (1997) 269-285
6. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 82 (2002) 47-95
7. Schreck R., Rieber P., and Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10 (1991) 2247-2258
8. 2 sensing. J. Biol. Chem. 275 (2000) 25130-25138
9. Loew O. A new enzyme of general occurrence in organisms. Science 11 (1900) 701-702
10. Reimer D.L., Bailley J., and Singh S.M. Complete cDNA and 5′ genomic sequences and multilevel regulation of the mouse catalase gene. Genomics 21 (1994) 325-336
11. McCord J.M., and Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244 (1969) 6049-6055
12. Hallywell B., and Gutteridge J.M.C. Free Radicals in Biology and Medicine. 4th Ed. (2007), Oxford University Press, Oxford
13. Fita I., and Rossmann M.G. The active center of catalase. J. Mol. Biol. 185 (1985) 21-37
14. Sezaki H., and Hashida M. Macromolecule-drug conjugates in targeted cancer chemotherapy. Crit. Rev. Ther. Drug Carrier Syst. 1 (1984) 1-38
15. Quan F., Korneluk R.G., Tropak M.B., and Gravel R.A. Isolation and characterization of the human catalase gene. Nucleic Acids Res. 14 (1986) 5321-5335
16. Nakashima H., Yamamoto M., Goto K., Osumi T., Hashimoto T., and Endo H. Isolation and characterization of the rat catalase-encoding gene. Gene 79 (1989) 279-288
17. Deisseroth A., and Dounce A.L. Catalase: physical and chemical properties, mechanism of catalysis, and physiological role. Physiol. Rev. 50 (1970) 319-375
18. Schisler N.J., and Singh S.M. Inheritance and expression of tissue-specific catalase activity during development and aging in mice. Genome 29 (1987) 748-760
19. Nishikawa M., Tamada A., Kumai H., Yamashita F., and Hashida M. Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. Int. J. Cancer 99 (2002) 474-479
20. Masters C., Pegg M., and Crane D. On the multiplicity of the enzyme catalase in mammalian liver. Mol. Cell Biochem. 70 (1986) 113-120
21. Chance B., Sies H., and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 59 (1979) 527-605
22. Chen X., Liang H., Van Remmen H., Vijg J., and Richardson A. Catalase transgenic mice: characterization and sensitivity to oxidative stress. Arch. Biochem. Biophys. 422 (2004) 197-210
23. Gaetani G.F., Ferraris A.M., Rolfo M., Mangerini R., Arena S., and Kirkman H.N. Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. Blood 87 (1996) 1595-1599
24. Mueller S., Riedel H.D., and Stremmel W. Direct evidence for catalase as the predominant H2O2 -removing enzyme in human erythrocytes. Blood 90 (1997) 4973-4978
25. Góth L., and Eaton J.W. Hereditary catalase deficiencies and increased risk of diabetes. Lancet 356 (2000) 1820-1821
26. Greenstein J.P., Jenrette W.V., and White J. The liver catalase activity of tumor-bearing rats and the effect of extirpation of the tumors. J. Natl. Cancer Inst. 2 (1941) 283-291
27. Yasmineh W.G., Parkin J.L., Caspers J.I., and Theologides A. Tumor necrosis factor/cachectin decreases catalase activity of rat liver. Cancer Res. 51 (1991) 3990-3995
28. Kwei K.A., Finch J.S., Thompson E.J., and Bowden G.T. Transcriptional repression of catalase in mouse skin tumor progression. Neoplasia 6 (2004) 440-448
29. Schriner S.E., Linford N.J., Martin G.M., Treuting P., Ogburn C.E., Emond M., Coskun P.E., Ladiges W., Wolf N., Van Remmen H., Wallace D.C., and Rabinovitch P.S. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308 (2005) 1909-1911
30. Li G., Chen Y., Saari J.T., and Kang Y.J. Catalase-overexpressing transgenic mouse heart is resistant to ischemia-reperfusion injury. Am. J. Physiol. 273 (1997) H1090-H1095
31. Hyoudou K., Nishikawa M., Kobayashi Y., Umeyama Y., Yamashita F., and Hashida M. PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radic. Biol. Med. 41 (2006) 1449-1458
32. Yabe Y., Koyama Y., Nishikawa M., Takakura Y., and Hashida M. Hepatocyte-specific distribution of catalase and its inhibitory effect on hepatic ischemia/reperfusion injury in mice. Free Radic. Res. 30 (1999) 265-274
33. Yabe Y., Kobayashi N., Nishikawa M., Mihara K., Yamashita F., Takakura Y., and Hashida M. Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharm. Res. 19 (2002) 1815-1821
34. Ashwell G., and Harford J. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 51 (1982) 531-554
35. Kino K., Tsunoo H., Higa Y., Takami M., Hamaguchi H., and Nakajima H. Hemoglobin-haptoglobin receptor in rat liver plasma membrane. J. Biol. Chem. 255 (1980) 9616-9620
36. Unger A., and Hershko C. Hepatocellular uptake of ferritin in the rat. Br. J. Haematol. 28 (1974) 169-179
37. Bomford A.B., and Munro H.N. Transferrin and its receptor: their roles in cell function. Hepatology 5 (1985) 870-875
38. Voorschuur A.H., Kuiper J., Van Noort W.L., and Van Berkel T.J. Zonal distribution of receptor binding of trypsin-activated α2-macroglobulin, α2-macroglobulin receptor-associated protein, lactoferrin and transferrin on rat liver parenchymal cells. Biochim. Biophys. Acta 1257 (1995) 288-292
39. Purdue P.E., and Lazarow P.B. Targeting of human catalase to peroxisomes is dependent upon a novel COOH-terminal peroxisomal targeting sequence. J. Cell Biol. 134 (1996) 849-862
40. Ogino T., Inoue M., Ando Y., Awai M., Maeda H., and Morino Y. Chemical modification of superoxide dismutase. Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin. Int. J. Pept. Protein Res. 32 (1988) 153-159
41. Gregoriadis G., Fernandes A., Mital M., and McCormack B. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol. Life Sci. 57 (2000) 1964-1969
42. Roberts M.J., Bentley M.D., and Harris J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54 (2002) 459-476
43. Veronese F.M., Caliceti P., Schiavon O., and Sergi M. Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation. Adv. Drug Deliv. Rev. 54 (2002) 587-606
44. Kamada H., Tsutsumi Y., Sato-Kamada K., Yamamoto Y., Yoshioka Y., Okamoto T., Nakagawa S., Nagata S., and Mayumi T. Synthesis of a poly(vinylpyrrolidone-co-dimethyl maleic anhydride) co-polymer and its application for renal drug targeting. Nat. Biotechnol. 21 (2003) 399-404
45. Abuchowski A., McCoy J.R., Palczuk N.C., van Es T., and Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252 (1977) 3582-3586
46. Yabe Y., Nishikawa M., Tamada A., Takakura Y., and Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. J. Pharmacol. Exp. Ther. 289 (1999) 1176-1184
47. Hyoudou K., Nishikawa M., Kobayashi Y., Kuramoto Y., Yamashita F., and Hashida M. Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. Clin. Exp. Metastasis 23 (2006) 269-278
48. Dedrick R.L., Myers C.E., Bungay P.M., and DeVita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62 (1978) 1-11
49. Flessner M.F., Fenstermacher J.D., Blasberg R.G., and Dedrick R.L. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am. J. Physiol. 248 (1985) H26-H32
50. Mattes M.J. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J. Natl. Cancer Inst. 79 (1987) 855-863
51. Schalkwijk J., van den Berg W.B., van de Putte L.B., Joosten L.A., and van den Bersselaar L. Cationization of catalase, peroxidase, and superoxide dismutase. Effect of improved intraarticular retention on experimental arthritis in mice. J. Clin. Invest. 76 (1985) 198-205
52. Kohen R., Kakunda A., and Rubinstein A. The role of cationized catalase and cationized glucose oxidase in mucosal oxidative damage induced in the rat jejunum. J. Biol. Chem. 267 (1992) 21349-21354
53. Blau S., Kohen R., Bass P., and Rubinstein A. The effect of local attachment of cationized antioxidant enzymes on experimental colitis in the rat. Pharm. Res. 17 (2000) 1077-1084
54. Ma S.F., Nishikawa M., Katsumi H., Yamashita F., and Hashida M. Liver targeting of catalase by cationization for prevention of acute liver failure in mice. J. Control. Release 110 (2006) 273-282
55. Nemoto T., Kawakami S., Yamashita F., and Hashida M. Efficient protection by cationized catalase against H2O2 injury in primary cultured alveolar epithelial cells. J. Control. Release 121 (2007) 74-80
56. Ma S.F., Nishikawa M., Hyoudou K., Takahashi R., Ikemura M., Kobayashi Y., Yamashita F., and Hashida M. Combining cisplatin with cationized catalase decreases nephrotoxicity while improving antitumor activity. Kidney Int. 72 (2007) 1474-1482
57. Krieger M., and Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu. Rev. Biochem. 63 (1994) 601-637
58. Hughes D.A., Fraser I.P., and Gordon S. Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur. J. Immunol. 25 (1995) 466-473
59. Furitsu H., Ogawara K., Fujita T., Yamashita F., Takakura Y., Sezaki H., and Hashida M. Pharmacokinetic analysis of scavenger receptor-mediated uptake of anionized proteins in the isolated perfused rat liver. Int. J. Pharm. 151 (1997) 15-26
60. Jansen R.W., Molema G., Ching T.L., Oosting R., Harms G., Moolenaar F., Hardonk M.J., and Meijer D.K. Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge, or the combination of these features. J. Biol. Chem. 266 (1991) 3343-3348
61. Grewal P.K., Uchiyama S., Ditto D., Varki N., Le D.T., Nizet V., and Marth J.D. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat. Med. 14 (2008) 648-655
62. Kawasaki N., Kawasaki T., and Yamashina I. Isolation and characterization of a mannan-binding protein from human serum. J. Biochem. 94 (1983) 937-947
63. Turner M.W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol. Today 17 (1996) 532-540
64. Opanasopit P., Shirashi K., Nishikawa M., Yamashita F., Takakura Y., and Hashida M. In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein. Am. J. Physiol. 280 (2001) G879-G889
65. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
66. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26 (2003) 1589-1596
67. Okada H., and Toguchi H. Biodegradable microspheres in drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 1-99
68. Young S., Wong M., Tabata Y., and Mikos A.G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Control. Release 109 (2005) 256-274
69. Gu F., Neufeld R., and Amsden B. Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device. J. Control. Release 117 (2007) 80-89
70. Hyoudou K., Nishikawa M., Ikemura M., Kobayashi Y., Mendelsohn A., Miyazaki N., Tabata Y., Yamashita F., and Hashida M. Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells. J. Control. Release 122 (2007) 151-158
71. McCord J.M. Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med. 312 (1985) 159-163
72. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am. J. Physiol. 284 (2003) G15-G26
73. - release by activated Kupffer cells upon hypoxia-reoxygenation. Am. J. Physiol. 261 (1991) G602-G607
74. Jaeschke H., and Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am. J. Physiol. 260 (1991) G355-G362
75. Selzner N., Rudiger H., Graf R., and Clavien P.A. Protective strategies against ischemic injury of the liver. Gastroenterology 125 (2003) 917-936
76. Jaeschke H., Bautista A.P., Spolarics Z., and Spitzer J.J. Superoxide generation by Kupffer cells and priming of neutrophils during reperfusion after hepatic ischemia. Free Radic. Res. Commun. 15 (1991) 277-284
77. Jaeschke H. Reactive oxygen and ischemia/reperfusion injury of the liver. Chem. Biol. Interact. 79 (1991) 115-136
78. Yabe Y., Kobayashi N., Nishihashi T., Takahashi R., Nishikawa M., Takakura Y., and Hashida M. Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives. J. Pharmacol. Exp. Ther. 298 (2001) 894-899
79. Loguercio C., and Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic. Biol. Med. 34 (2003) 1-10
80. Finkel T., and Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 408 (2000) 239-247
81. Finkel T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 15 (2003) 247-254
82. Viatour P., Merville M.P., Bours V., and Chariot A. Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem. Sci. 30 (2005) 43-52
83. Kang J.S., Wanibuchi H., Morimura K., Wongpoomchai R., Chusiri Y., Gonzalez F.J., and Fukushima S. Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol. Appl. Pharmacol. 228 (2008) 295-300
84. Lu S.C., Huang Z.Z., Yang H., and Tsukamoto H. Effect of thioacetamide on the hepatic expression of γ-glutamylcysteine synthetase subunits in the rat. Toxicol. Appl. Pharmacol. 159 (1999) 161-168
85. Kamath P.S., Tyce G.M., Miller V.M., Edwards B.S., and Rorie D.K. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 30 (1999) 401-407
86. Bruck R., Aeed H., Schey R., Matas Z., Reifen R., Zaiger G., Hochman A., and Avni Y. Pyrrolidine dithiocarbamate protects against thioacetamide-induced fulminant hepatic failure in rats. J. Hepatol. 36 (2002) 370-377
87. Díez-Fernández R.C., Boscá L., Fernández-Simón L., Alvarez A., and Cascales M. elationship between genomic DNA ploidy and parameters of liver damage during necrosis and regeneration induced by thioacetamide. Hepatology 18 (1993) 912-918
88. Hyoudou K., Nishikawa M., Kobayashi K., Kuramoto Y., Yamashita F., and Hashida M. Analysis of in vivo nuclear factor-κB activation during liver inflammation in mice: prevention by catalase delivery. Mol. Pharmacol. 71 (2007) 446-453
89. Andrés D., Sánchez-Reus I., Bautista M., and Cascales M. Depletion of Kupffer cell function by gadolinium chloride attenuates thioacetamide-induced hepatotoxicity. Expression of metallothionein and HSP70. Biochem. Pharmacol. 66 (2003) 917-926
90. Su G.L., Klein R.D., Aminlari A., Zhang H.Y., Steinstraesser L., Alarcon W.H., Remick D.G., and Wang S.C. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 31 (2000) 932-936
91. Uchikura K., Wada T., Hoshino S., Nagakawa Y., Aiko T., Bulkley G.B., Klein A.S., and Sun Z. Lipopolysaccharides induced increases in Fas ligand expression by Kupffer cells via mechanisms dependent on reactive oxygen species. Am. J. Physiol. 287 (2004) G620-G626
92. × radical. J. Biol. Chem. 265 (1990) 8392-8399
93. Wang D.H., Ishii K., Zhen L.X., and Taketa K. Enhanced liver injury in acatalasemic mice following exposure to carbon tetrachloride. Arch. Toxicol. 70 (1996) 189-194
94. Takagi T., Kitano M., Masuda S., Tokuda H., Takakura Y., and Hashida M. Augmented inhibitory effect of superoxide dismutase on superoxide anion release from macrophages by direct cationization. Biochim. Biophys. Acta 1335 (1997) 91-98
95. Nishikawa M., Hasegawa S., Yamashita F., Takakura Y., and Hashida M. Electrical charge on protein regulates its absorption from the rat small intestine. Am. J. Physiol. 282 (2002) G711-G719
96. Ishimoto N., Nemoto T., Nagayoshi K., Yamashita F., and Hashida M. Improved anti-oxidant activity of superoxide dismutase by direct chemical modification. J. Control. Release 111 (2006) 204-211
97. Nishida K., Mihara K., Takino T., Nakane S., Takakura Y., Hashida M., and Sezaki H. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharm. Res. 8 (1991) 437-444
98. Fujita T., Nishikawa M., Ohtsubo Y., Ohno J., Takakura Y., Sezaki H., and Hashida M. Control of in vivo fate of albumin derivatives utilizing combined chemical modification. J. Drug Target. 2 (1994) 157-165
99. Ma S.F., Nishikawa M., Katsumi H., Yamashita F., and Hashida M. Cationic charge-dependent hepatic delivery of amidated serum albumin. J. Control. Release 102 (2005) 583-594
100. Mihara K., Mori M., Hojo T., Takakura Y., Sezaki H., and Hashida M. Disposition characteristics of model macromolecules in the perfused rat kidney. Biol. Pharm. Bull. 16 (1993) 158-162
101. Mihara K., Oka Y., Sawai K., Takakura Y., and Hashida M. Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol. J. Drug Target. 2 (1994) 317-321
102. Mihara K., Sawai K., Takakura Y., and Hashida M. Manipulation of renal disposition of human recombinant superoxide dismutase by chemical modification. Biol. Pharm. Bull. 17 (1994) 296-301
103. Kostova I. Platinum complexes as anticancer agents. Recent Patents Anticancer Drug Discov. 1 (2006) 1-22
104. Yao X., Panichpisal K., Kurtzman N., and Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 334 (2007) 115-124
105. Zhang J.G., and Lindup W.E. Role of mitochondria in cisplatin-induced oxidative damage exhibited by rat renal cortical slices. Biochem. Pharmacol. 45 (1993) 2215-2222
106. Baliga R., Ueda N., Walker P.D., and Shah S.V. Oxidant mechanisms in toxic acute renal failure. Drug Metab. Rev. 31 (1999) 971-997
107. Gonzalez V.M., Fuertes M.A., Alonso C., and Perez J.M. Is cisplatin-induced cell death always produced by apoptosis?. Mol. Pharmacol. 59 (2001) 657-663
108. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
109. Engers R., and Gabbert H.E. Mechanisms of tumor metastasis: cell biological aspects and clinical implications. J. Cancer Res. Clin. Oncol. 126 (2000) 682-692
110. Bogenrieder T., and Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22 (2003) 6524-6536
111. Kim R., Emi M., Tanabe K., and Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66 (2006) 5527-5536
112. Gupta G.P., and Massagué J. Cancer metastasis: building a framework. Cell 127 (2006) 679-695
113. Nishikawa M., Hyoudou K., Kobayashi Y., Umeyama Y., Takakura Y., and Hashida M. Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. J. Control. Release 109 (2005) 101-107
114. Serrano J., Palmeira C.M., Kuehl D.W., and Wallace K.B. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim. Biophys. Acta 1411 (1999) 201-205
115. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
116. Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett. 266 (2008) 53-59
117. Morikawa K., Shimokawa H., Matoba T., Kubota H., Akaike T., Talukder M.A., Hatanaka M., Fujiki T., Maeda H., Takahashi S., and Takeshita A. Pivotal role of Cu,Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest. 112 (2003) 1871-1879
118. Shimokawa H., and Matoba T. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pharmacol Res. 49 (2004) 543-549
119. Khatib A.M., Auguste P., Fallavollita L., Wang N., Samani A., Kontogiannea M., Meterissian S., and Brodt P. Characterization of the host proinflammatory response to tumor cells during the initial stages of liver metastasis. Am. J. Pathol. 167 (2005) 749-759
120. Kobayashi Y., Nishikawa M., Hyoudou K., Yamashita F., and Hashida M. Hydrogen peroxide-mediated nuclear factor κB activation in both liver and tumor cells during initial stages of hepatic metastasis. Cancer Sci. 99 (2008) 1546-1552
121. Auguste P., Fallavollita L., Wang N., Burnier J., Bikfalvi A., and Brodt P. The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. Am. J. Pathol. 170 (2007) 1781-1792
122. Nishikawa M., Tamada A., Hyoudou K., Umeyama Y., Takahashi Y., Kobayashi Y., Kumai H., Ishida E., Staud F., Yabe Y., Takakura Y., Yamashita F., and Hashida M. Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clin. Exp. Metastasis 21 (2004) 213-221
123. Curran S., and Murray G.I. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur. J. Cancer 36 (2000) 1621-1630
124. Hyoudou K., Nishikawa M., Umeyama Y., Kobayashi Y., Yamashita F., and Hashida M. Inhibition of metastatic tumor growth in mouse lung by repeated administration of polyethylene glycol-conjugated catalase: quantitative analysis with firefly luciferase-expressing melanoma cells. Clin. Cancer Res. 10 (2004) 7685-7691
125. Murrell G.A., Francis M.J., and Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J. 265 (1990) 659-665
126. Storz P. Reactive oxygen species in tumor progression. Front. Biosci. 10 (2005) 1881-1896
127. Oldham K.M., and Bowen P.E. Oxidative stress in critical care: is antioxidant supplementation beneficial?. J. Am. Diet. Assoc. 98 (1998) 1001-1008
128. Bouvy N.D., Marquet R.L., Jeekel J., and Bonjer H.J. Laparoscopic surgery is associated with less tumour growth stimulation than conventional surgery: an experimental study. Br. J. Surg. 84 (1997) 358-361
129. van den Tol P.M., van Rossen E.E., van Eijck C.H., Bonthuis F., Marquet R.L., and Jeekel H. Reduction of peritoneal trauma by using nonsurgical gauze leads to less implantation metastasis of spilled tumor cells. Ann. Surg. 227 (1998) 242-248
130. Gunduz N., Fisher B., and Saffer E.A. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 39 (1979) 3861-3865
131. Arai K., Asakura T., and Nemir Jr. P. Effect of local tumor removal and retained oncolysate on lung metastasis. J. Surg. Res. 53 (1992) 30-38
132. Kodama M., Kodama T., Nishi Y., and Totani R. Does surgical stress cause tumor metastasis?. Anticancer Res. 12 (1992) 1603-1616
133. Smolle J., Soyer H.P., Smolle-Jüttner F.M., Rieger E., and Kerl H. Does surgical removal of primary melanoma trigger growth of occult metastases? An analytical epidemiological approach. Dermatol. Surg. 23 (1997) 1043-1046
134. Tsuchiya Y., Sawada S., Yoshioka I., Ohashi Y., Matsuo M., Harimaya Y., Tsukada K., and Saiki I. Increased surgical stress promotes tumor metastasis. Surgery 133 (2003) 547-555
135. Hyoudou K., Nishikawa M., Kobayashi Y., Ikemura M., Yamashita F., and Hashida M. SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clin. Exp. Metastasis 25 (2008) 531-536
136. Onoda J.M., Piechocki M.P., and Honn K.V. Radiation-induced increase in expression of the α IIb β 3 integrin in melanoma cells: effects on metastatic potential. Radiat. Res. 130 (1992) 281-288
137. Shaughnessy S.G., Whaley M., Lafrenie R.M., and Orr F.W. Walker 256 tumor cell degradation of extracellular matrices involves a latent gelatinase activated by reactive oxygen species. Arch. Biochem. Biophys. 304 (1993) 314-321
138. Sellak H., Franzini E., Hakim J., and Pasquier C. Reactive oxygen species rapidly increase endothelial ICAM-1 ability to bind neutrophils without detectable upregulation. Blood 83 (1994) 2669-2677
139. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., and Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98 (1996) 2572-2579
140. 2 exposure. Lab. Invest. 77 (1997) 533-539
141. Oosterling S.J., van der Bij G.J., van Egmond M., and van der Sijp J.R. Surgical trauma and peritoneal recurrence of colorectal carcinoma. Eur. J. Surg. Oncol. 31 (2005) 29-37
142. van Rossen M.E., Stoop M.P., Hofland L.J., van Koetsveld P.M., Bonthuis F., Jeekel J., Marquet R.L., and van Eijck C.H. Red blood cells inhibit tumour cell adhesion to the peritoneum. Br. J. Surg. 86 (1999) 509-513
143. van Rossen M.E., Sluiter W., Bonthuis F., Jeekel H., Marquet R.L., and van Eijck C.H. Scavenging of reactive oxygen species leads to diminished peritoneal tumor recurrence. Cancer Res. 60 (2000) 5625-5629
144. Hyoudou K., Nishikawa M., Kobayashi Y., Mukai S., Ikemura M., Kuramoto Y., Yamashita F., and Hashida M. Inhibition of peritoneal dissemination of tumor cells by cationized catalase in mice. J. Control. Release 119 (2007) 121-127
145. Ozeki M., and Tabata Y. In vivo degradability of hydrogels prepared from different gelatins by various cross-linking methods. J. Biomater. Sci. Polym. Ed. 16 (2005) 549-561